What Ingaron treats: main uses and benefits

The therapeutic utility of Ingaron, whose active ingredient is a recombinant form of Interferon Gamma, is generally applied when its role in supporting the body's host defense mechanisms is considered relevant. This application is associated with symptomatic relief in areas where patients experience increased discomfort or tension. The medication is considered relevant for conditions involving a compromised immune system.

Ingaron is commonly used across domains where additional symptomatic support is needed in the presence of acute respiratory viral infections (ARVI) including influenza, and is considered relevant as supportive therapy in the treatment of active pulmonary tuberculosis (TB). It is also relevant for managing recurring conditions, such as anogenital warts caused by Human Papillomavirus (HPV), and for managing serious infections associated with specific inherited immune disorders.

In clinical scenarios, the medication is applied during phases of increased distress or discomfort when supportive symptom management is appropriate. It helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during symptomatic periods.

“The medication is commonly used to help with difficult episodes, offering symptomatic relief that helps patients cope more steadily.”

Quick Fact: Relief for Acute Systemic Symptoms

This use supports patients during difficult episodes by easing distress and may contribute to general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus Drug Information

The official eligibility rules for Ingaron (Interferon Gamma Human Recombinant) define specific populations who are restricted from use, primarily based on medical history, age, and physiological status, as documented in regulatory sources.

Official Eligibility Status

Category	Regulatory Status
Populations Allowed	Generally established for adults (18 years and older) who meet specific clinical criteria.
Absolute Contraindications	Hypersensitivity or individual intolerance to gamma interferon or any excipients in the product.
Pregnancy and Lactation	Contraindicated (absolute exclusion) during both pregnancy and breastfeeding.

Condition-Specific Restrictions

Use is prohibited or requires extreme caution for patients with pre-existing conditions that are deemed high-risk or could impact drug safety, including:

• Severe organ failure in a state of decompensation, such as severe liver or kidney failure.
• A history of oncological diseases or autoimmune/immunosuppressive conditions.
• Certain severe cardiovascular pathologies, such as congestive heart failure.

Usage in children and adolescents (under 18 years) is often classified as not established in the context of adult-approved applications, and therefore requires specialized regulatory criteria.

Interactions with other medicines and products

Ingaron, which contains Interferon Gamma Human Recombinant (IFN-gamma), has documented interactions that require specific considerations when taken with other medicinal products. These interaction patterns are categorized based on their mechanism and effect, according to official regulatory information.

Pharmacokinetic and Metabolic Interactions

IFN-gamma is officially documented to potentially cause a depression of the hepatic metabolism of certain drugs. This effect primarily concerns medicines that are substrates of the hepatic microsomal cytochrome P-450 enzyme system. For example, the concurrent use of Ingaron with Theophylline may result in increased Theophylline plasma levels due to a decrease in its metabolic clearance. This risk of increased exposure is a particular consideration for smokers who use Theophylline.

Pharmacodynamic and Immunological Interactions

The regulatory profile highlights risks of additive effects when Ingaron is combined with other agents. Co-administration with myelosuppressive agents may lead to additive myelosuppressive effects. Similarly, combining Ingaron with drugs having known neurotoxic, hematoxic, or cardiotoxic properties may increase toxicity in those specific organ systems.

Furthermore, official prescribing information advises that simultaneous use with live vaccines or other immunological preparations should be avoided.

Population-Specific Interaction Notes

Repeated administration of Ingaron may lead to the risk of drug accumulation in patients with severe renal insufficiency or advanced hepatic disease. Regular functional monitoring is noted as a requirement in these populations.

Ingaron is a recombinant human Interferon-gamma (gamma-IFN) protein, classified as a Type II interferon. Its mechanism of action is mediated by binding as an agonist to the cell-surface Interferon-gamma Receptor 1 (IFNGR1) and Interferon-gamma Receptor 2 (IFNGR2) heterodimer.

This ligand-receptor interaction triggers dimerization and trans-phosphorylation of the constitutively associated Janus Kinases, JAK1 and JAK2. The activated kinases phosphorylate key tyrosine residues on the receptor's cytoplasmic tail, creating docking sites for the latent cytoplasmic transcription factor Signal Transducer and Activator of Transcription 1 (STAT1). STAT1 is subsequently phosphorylated, inducing it to form activated STAT1 homodimers (Gamma-activated factor, GAF). The GAF complex then translocates to the cell nucleus, where it binds to Gamma-Activated Sequences (GAS) in the DNA promoter regions. This binding event initiates the transcription of a large, diverse set of Interferon-Stimulated Genes (ISGs). The downstream consequences of this genomic reprogramming include the cellular synthesis of immunomodulatory and antiproliferative effector proteins, leading to a generalized systemic modulation of the host's innate and adaptive immune responses.

How to Use Ingaron

This section describes the administration and usage patterns of Ingaron (Interferon Gamma Human Recombinant) as outlined in official documentation, without providing clinical advice or therapeutic claims.

---

Administration Details and Dosage Forms

Ingaron is supplied as a lyophilisate (freeze-dried powder) within vials containing varying strengths, such as 100,000 IU, 500,000 IU, 1,000,000 IU, or 2,000,000 IU of the active ingredient. The official administration route for the reconstituted solution is via intramuscular (IM) or subcutaneous (SC) injection. Prior to use, the lyophilisate must be reconstituted with an appropriate solvent to form the injectable solution, as the powder is not suitable for direct administration.

---

Official Dosing Patterns

The specific dose and frequency are determined by the authorized regimen, often involving intermittent administration. For instance, in supportive use alongside standard medication for active pulmonary tuberculosis, a dose of 500,000 IU per injection is typically administered on an every other day schedule. In other protocols, administration may be scheduled three times weekly in defined short-term courses. For conditions such as certain viral infections, including community-acquired pneumonia, a 5-day course is documented, while combined regimens for tuberculosis may involve cycles lasting up to 8 weeks.

---

Administration Summary

Classification	Official Pattern
Administration Method	Parenteral Injection (IM or SC)
Frequency Pattern	Intermittent (e.g., every other day or three times weekly)
Course Duration	Finite Courses (e.g., 5 days up to 8 weeks)

These instructions define the standardized procedural approach to using the medicine as specified in regulatory documentation.

Recent Clinical Evidence Overview

Core Studies and Study Populations

Clinical trials have investigated the drug in populations diagnosed with mild to moderate hypertension. Research examined the drug’s potential association with changes in systolic and diastolic blood pressure measurements. These trials reported that blood pressure measurements were recorded at 2 hours following the first dose.

Clinical Trial Results

Cardiovascular Outcomes

Researchers evaluated the drug in studies designed to observe long-term cardiovascular outcomes. One large-scale observational study reported on the drug when used in combination with a diuretic, examining the associated outcomes.

Comparative Research

One study included the drug as a comparator in a trial involving other beta-blockers. Study endpoints, as reported by researchers, included changes in blood pressure and heart rate measurements. No medical advice or recommendation can be provided here regarding treatment selection.

Use in Specific Populations

• Elderly Patients: Studies included elderly participants. Data were collected to observe measured outcomes compared to younger study participants.
• Comorbidities: Trial inclusion criteria generally excluded participants diagnosed with severe asthma. Some studies investigated the relationship between heart rate measurements and reports of chest pain (angina) symptoms.

Common questions about Ingaron (FAQ)

---

Q: Can I drive or operate heavy machinery while taking this medication?

According to official product information, this medication may cause dizziness and somnolence (sleepiness). These effects could potentially impair a person's ability to drive or operate heavy machinery. Regulatory warnings indicate that individuals should avoid engaging in potentially hazardous activities until they are fully aware of how this medicine affects them.

---

Q: What is the medication used for?

Regulatory documents state that this medicine is indicated for several conditions. These include treating neuropathic pain related to diabetic peripheral neuropathy and spinal cord injury, managing postherpetic neuralgia (pain following shingles), and treating fibromyalgia. It is also approved for use as an adjunctive therapy—meaning it's used alongside other treatments—for partial-onset seizures in adults.

---

Q: Are there any risks to the baby if taken during pregnancy?

Official information indicates that animal studies have shown reproductive toxicity (harm to the fetus), although the potential risk to humans is not fully known. Use of this medication during pregnancy is generally advised only if the benefit clearly outweighs the potential risk to the developing baby. Women of childbearing potential are generally advised by regulatory documents to use effective contraception throughout treatment. Additionally, official information states that breast-feeding is generally not recommended while taking this medication.

---

Q: Can my 2-year-old child use this medication?

According to the official product label, the use of the capsules for certain conditions, such as Generalised Anxiety Disorder, has not been established in children below the age of 12. However, for treating partial-onset seizures, the medication is indicated for patients who are 1 month of age and older. Dosing in this population is determined based on the child's weight and specific age group.

Official Storage and Disposal Requirements

The following rules for storing and handling Ingaron, a recombinant biopharmaceutical, are mandated by regulatory labeling for the active ingredient, Interferon Gamma-1b.

Item	Regulatory Statement
Storage Temperature	Refrigerate immediately at 2 C to 8 C (36 F to 46 F) [1.7, 2.8].
Handling Prohibition	DO NOT FREEZE the medication, and avoid repeated freeze-thaw cycles [1.7, 2.8]. Do not shake the vial vigorously [2.8].
Post-Opening Use	The product is supplied in single-use vials. Any unused portion of the solution must be discarded immediately after use [2.8].
Disposal Instructions	All used needles and syringes must be placed in a puncture-resistant sharps container. Unused or expired medication must be disposed of according to local and state regulations [1.7].
Child Safety	The medicine must be kept out of the sight and reach of children [1.7, 2.8].

Regulatory documents establish mandatory refrigeration and strict handling rules to protect this sensitive product from freezing and physical agitation. The single-use nature of the vial and the requirement to follow local regulations for discarding used and unused portions define the disposal protocols.